Atossa Therapeutics Inc
General ticker "ATOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $147.8M
Atossa Therapeutics Inc follows the US Stock Market performance with the rate: 29.1%.
Estimated limits based on current volatility of 3.3%: low 0.96$, high 1.03$
Factors to consider:
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [0.39$, 1.06$]
- 2023-12-31 to 2024-12-30 estimated range: [0.38$, 1.00$]
Financial Metrics affecting the ATOS estimates:
- Negative: Non-GAAP EPS, $ of -0.21 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -19.87 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
Short-term ATOS quotes
Long-term ATOS plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $14.61MM | $20.52MM | $27.69MM |
| Operating Income | $-14.61MM | $-20.52MM | $-27.69MM |
| Non-Operating Income | $-3.22MM | $-0.09MM | $0.73MM |
| R&D Expense | $6.61MM | $9.21MM | $15.08MM |
| Income(Loss) | $-17.83MM | $-20.61MM | $-26.96MM |
| Profit(Loss) | $-17.83MM | $-20.61MM | $-26.96MM |
| Stockholders Equity | $27.17MM | $138.14MM | $117.96MM |
| Inventory | $1.92MM | $2.60MM | $4.14MM |
| Assets | $42.84MM | $141.26MM | $123.53MM |
| Operating Cash Flow | $-11.57MM | $-16.47MM | $-20.76MM |
| Capital expenditure | $0.01MM | $0.01MM | $0.03MM |
| Investing Cash Flow | $-0.01MM | $-0.01MM | $-4.73MM |
| Financing Cash Flow | $38.55MM | $113.30MM | $0.00MM |
| Earnings Per Share* | $-1.87 | $-0.18 | $-0.21 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.